30% relative risk reduction in all-cause hospitalizations at 1 month after a heart failure hospitalization (P<0.05).

Reduction of risk from the first month onwards, ranging from 21% to 30% within the first 3 months following a heart failure hospitalization.

Effect of ivabradine on early rehospitalizations during the vulnerable phase after a first hospitalization for worsening heart failure. Abbreviation: IRR, incidence rate ratio.

Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182-1189.